Universität Hamburg - der Forschung, der Lehre, der Bildung, zur Homepage
Professur für Health Care Management
Professurfür Health Care Management

Foto: UHH

Publikationen

Peer-reviewed journal articles

Accepted, online first & in print

  • Birkner B, Rech J, Edelmann E, Verheyen F, Schett G, Stargardt T (2022): Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting, Rheumatology, accepted & in print, https://doi.org/10.1093/rheumatology/keac472. 

2023

  • König HH, Neumann-Böhme S, Sabat I, Schreyögg J, Torbica A, van Exel J, Barros P, Stargardt T, Hajek A (2023): Health-related quality of life in seven European countries throughout the course of the COVID-19 pandemic: Evidence from the European COvid Survey (ECOS), Quality of Life Research, https://doi.org/10.1007/s11136-022-03334-5.
  • Wang SY, Cantarelli P, Groene O, Stargardt T, Belle N (2023): Patient expectations do matter - experimental evidence on antibiotic prescribing decisions among hospital-based physicians, Health Policy, 128:11-17, https://doi.org/10.1016/j.healthpol.2022.11.009.
  • Vadia R, Malyar N, Stargardt T (2023): Cost-utility analysis of early versus delayed endovascular intervention in critical limb-threatening ischemia (CLTI) patients with rest-pain, Journal of Vascular Surgery, 77(1):299-308, https://doi.org/10.1016/j.jvs.2022.07.007.
  • Böhm A, Schneider U, Stargardt T (2023): Economic Effects of Fixed-Dose Versus Loose-Dose Combination Therapy for Type 2 Diabetes Patients, Applied Health Economics and Health Policy, 21(1): 109-118, https://doi.org/10.1007/s40258-022-00760-x.

2022

  • Büssgen M, Stargardt T (2022): Changes in Launch Delay and Availability of Pharmaceuticals in 30 European Markets over the Past Two Decades, BMC Health Services Research, BMC Health Services Research, 22, 1457. https://doi.org/10.1186/s12913-022-08866-7
  • Hofer F, Schreyögg J, Stargardt T (2022): Effectiveness of a home telemonitoring program for patients with chronic obstructive pulmonary disease in Germany: evidence from the first three years, PLOS ONE, https://doi.org/10.1371/journal.pone.0267952. 

  • Hajek A, Sabat I, Neumann-Böhme S, Schreyögg J, Barros PP, Stargardt T, König HH (2022): Prevalence and determinants of probable depression and anxiety during the COVID-19 pandemic in seven countries: Longitudinal evidence from the European COvid Survey (ECOS), Journal of Affective Disorders, 299: 517-524, https://doi.org/10.1016/j.jad.2021.12.029.

2021

  •  Böhm A, Schneider U, Aberle J, Stargardt T (2021): Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes. PLOS ONE, https://doi.org/10.1371/journal.pone.0250993. 

  • Chandler T, Neumann-Böhme S, Sabat I, Barros PP, Brouwer W, van Exel J, Schreyögg J, Torbica A, Stargardt T (2021): Blood donation in times of crisis: early insight into the impact of COVID-19 on blood donors and their motivation to donate across European countries, Vox Sanguinis, 116(10):1031-1041, https://doi.org/10.1111/vox.13103. 

  • Varghese NE, Sabat I, Neuman-Böhme S, Schreyögg J, Stargardt T, Torbica A, van Exel J, Barros PP, Brouwer W (2021): Risk Communication during COVID-19: A Descriptive Study on Familiarity with, Adherence to and Trust in the WHO Preventive Measures, PLOS ONE, https://doi.org/10.1371/journal.pone.0250872.
  • Pott C, Stargardt T, Schneider U, Frey S (2021)
    Do discontinuities in marginal reimbursement affect inpatient psychiatric care in Germany?, European Journal for Health Economics, 22(1): 101-114, doi: 10.1007/s10198-020-01241-5
  • Vadia R, Stargardt T (2021)
    Impact of Guidelines on the Diffusion of Medical Technology: A Case Study of Cardiac Resynchronization Therapy in the UK, Applied Health Economics and Health Policy, 19(2): 243-252, doi: 10.1007/s40258-020-00610-8

2020

  • Böhm AK, Jensen ML, Sørensen MR, Stargardt T (2020)
    Real-World Evidence of User Engagement With Mobile Health for Diabetes Management: Longitudinal Observational Study, JMIR Mhealth Uhealth, 8(11):e22212.doi:10.2196/22212
  • Blankart KE, Stargardt T (2020)
    The impact of drug quality ratings from health technology assessment on the adoption of new drugs by physicians in Germany, Health Economics, 29(S1): 63-82
  • Sabat I, Neumann-Böhme S, Varghese NE, Barros PP, Brouwer W, van Exel J, Schreyögg J, Stargardt T (2020)
    United but divided: policy responses and people`s perceptions in the EU during the COVID-19 outbreak, Health Policy, 124(9):909-918
  • Baumann M, Stargardt T, Frey S (2020)
    Cost-utility of internet-based cognitive behavioral therapy in unipolar depression: A Markow model simulation, Applied Health Economics and Health Policy, 18(4):567-578
  • Neumann-Böhme S, Varghese NE, Sabat I, Barros PP, Brouwer W, van Exel J, Schreyögg J, Stargardt T (2020)
    Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19, European Journal for Health Economics, 21(7):977-982
  • Birkner B, Rech J, Stargardt T (2020)
    Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis, Plos one, 15(1):e0226754, doi: 10.1371/journal.pone.0226754
  • Chandler T, Hiller J, Peine S, Stargardt T (2020)
    Blood donation and donors: insights from a large German teaching hospital, Vox Sanguinis, 115(1):27-35

2019

  • Frey S, Stargardt T, Schneider U, Schreyögg J (2019)
    The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective, Pharmacoeconomics, 37(8):1029-1039
  • Guhl D, Stargardt T, Blankart KE (2019)
    Service Quality and perceived customer value in community pharmacies, Health Services Management Research, 32(1):36-48 

2018

  • Hofer F, Kauczor HU, Stargardt T (2018)
    Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach, Lung cancer, 124():189-198
  •  Fischer K, Koch T, Kostev K, Stargardt T (2018)
    The impact of physician-level drug budgets on prescribing behaviour, European Journal for Health Economics, 19(2):213-222

  • Stargardt T, Eckmann C, Bouza E, Rossolini GM, Grossi PA (2018)
    • Attitudes of physicians from 10 European countries on adherence and how teatment modalities in ABSSSI affect adherence: results from a Delphi survey, European Journal of Clinical Microbiology & Infectious Diseases

2017

  • Blankart CB, Stargardt T (2017)
    Preferred supplier contracts in post-patent prescription drup markets, Health Care Management Science, 20(3):419-432
  • Achelrod D, Schreyögg J, Stargardt T (2017)
    Health-economic evaluation of home telemonitoring for COPD in Germany: evidence from a large population-based cohort, European Journal of Health Economics, 18(7):869-892
  • Lauenroth V, Stargardt T (2017)
    Pharmaceutical Pricing in Germany: How is Value Determined within the Scope of AMNOG?, Value in Health, 20(7):927-935

2016

  • Hostenkamp G, Fischer KE, Borch-Johnsen K (2016)
    Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark, Health Policy, 120(12):1404-1411
  • Müller D, Gerber-Grote A, Stollenwerk B, Stock S, Auweiler PWP, Frey S, ... Hellmich M (2016)
    Reporting health care decision models: a prospective reliability study of a multidimensional evaluation framework.Expert Review of Pharmacoeconomics & Outcomes Research, 16(5):619-627
  • Achelrod D, Welte T, Schreyögg J, Stargardt T (2016)
    Costs and Outcomes of the German Disease Management Programme (DMP) for Chronic Ostructive Pulmonary Disease (COPD) - A large population-based cohort study, Health Policy, 120(9):1029-39
  • Fischer K, Heisser T, Stargardt T (2016)
    Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia, Health Policy, 120(10):1115-20
  • Hofer F, Achelrod D, Stargardt T (2016)
    Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany, Applied Health Economics and Health Policy, 14(6):691-701
  • Fischer K, Stargardt T (2016)
    The diffusion of generics after patent expiry in Germany, European Journal of Health Economics, 17(8):1027-40
  • Guhl D, Fischer K, Schneider U, Stargadt T (2016)
    Dispensing behaviour in pharmacy markets, Health Policy, 120(2):190-7.
  • Frey S, Blankart CB, Stargardt T (2016)
    Economic burden and quality of life effects of chronic lymphocytic leukemia: A systematic review of the literature, Pharmacoeconomics. 34(5): 479-498.

2015

  • Achelrod D, Wenzel U, Frey S (2015)
    Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. American Journal of Hypertension, 28(3), 355-361. http://ajh.oxfordjournals.org/content/28/3/355

2014

  • Achelrod D, Blankart C, Linder R, Kodolitsch Y, Stargardt T (2014)                                                                
    The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study, Orphanet Journal of Rare Diseases; 9:90.

2013

  • Haas L, Stargardt T, Schreyögg J, Schlösse R, Danzer G, Klapp B (2013)
    The trade-off between costs and quality of care in the treatment of psychosomatic patients with somato form pain disorder, Applied Health Economics and Health Policy, 11(4): 359-368.
  • Fischer K. (2013)
    Ansätze zur empirischen Analyse von Entscheidungen über die Erstattungsfähigkeit von Gesundheitstechnologien in industrialisierten Ländern. RPG Recht und Politik im Gesundheitswesen. 2013; 19(3): 67-81
  • Blankart R, Koch T, Linder R, Verheyen F, Schreyögg J, Stargardt T (2013)
    Cost of illness and economic burden of chronic lymphocytic leukemia, Orphanet Jourmal of Rare Diseases, 8(1):32.

2012

2011

2010

2009

2008

before 2007

Non peer-reviewed publications

Books and book chapters

  • Busse R, Schreyögg J, Stargardt T [Hrsg.] (2017)
    Management im Gesundheitswesen, 4. Auflage, Springer
  • Stargardt T, Vandoros S (2014)
    Pharmaceutical Pricing and Reimbursement Regulation in Europe, in: Culyer JA (ed.), Encyclopedia of Health Economics, Vol 3. San Diego: Elsevier, 29-36.

  • Blankart R, Roll K, Heimeshoff M, Stargardt T, Schreyögg J (2014)
    Innovationsbedearf in der Gesundheitswirtschaft im Spiegel der Forschung, in: Bieber D, Geiger M (Hrsg.): Personenbezogene Dienstleistungen im Kontext komplexer Wertschöpfung, Springer, pp. 257-267.
  • Stargardt T, Schreyögg J (2012)
    Leistungsmanagement in der Arzneimittelindustrie, in: Busse R, Schreyögg J, Stargardt T: Management im Gesundheitswesen, Springer, pp. 128-148.
  • Stargardt T, Tiemann O (2012)
    Personalmanagement im Gesundheitswesen - Einführung und methodische Grundlagen, in: Busse R, Schreyögg J, Stargardt T: Management im Gesundheitswesen, Springer, pp. 336-338.
  • Schreyögg J, Stargardt T (2009)
    Leistungsmanagement in der Arzneimittelindustrie, in: Busse R, Schreyögg J, Gericke C: Management im Gesundheitswesen, Springer, pp. 122-140.
  • Schreyögg J, Stargardt T (2006)
    Leistungsmanagement in der Arzneimittelindustrie, in: Busse R, Schreyögg J, Gericke C: Management im Gesundheitswesen, Springer, pp. 123- 141.

Other publications

  • Helms TM, Gulba D, Ahrens I, Schäfer A, Hankowitz J, Kuhlencordt P, Lipp HP, Nikol S, Riess H, Stargardt T, Bramlage P (2017)
    Therapie und Sekundärprävention der venösen Thromboembolie - Orale Antikoagulation im Wandel, Deutsche Medizinische Wochenschrift 142:1-8
  • Helms TM, Silber S, Schäfer A, Masuhr F, Palm F, Darius H, Schrör K, Bänsch S, Bramlage P, Hankowitz J, Karle CA, Stargardt T, Weil J, Geller JC (2016)
    Konsenuspapier: Schlaganfallprophylaxe bei Patienten mit nichtvalvulärem Vorhofflimmern, Herzschrittmachertherapie + Elektrophysiologie, 1-2
  • Vandoros S, Stargardt T (2013)
    Authors´ response to Health service expenditures and efficiencies in Greece, Health Policy, 111(2): 208-209
  • Schreyögg J, Schultz C, Stargardt T (2012)
    Focus on designing health care structures and services for rare diseases, Health Policy, 105(2-3):107-109.
  • Roll K, Stargardt T, Schreyögg J (2012)
    Einfluss von Versichertenstatus und Einkommen auf die Wartezeit im ambulanten Bereich, Monitor Versorgungsforschung, 5(5):27-29.
  • Stargardt T (2006)
    Focus on Germany, Reference Pricing, in: Pharmaceutical Marketing Europe, 3(1):32-34.
  • Farhauer O, Borchardt K, Stargardt T (2005)
    Bürgerversicherung * Systematisierung und Bewertung der Reformvarianten, in: Wirtschaftswissenschaftliches Studium WiSt, 34(6):308-314.
Sortieren nach: